Smith Graham & Co. Investment Advisors LP reduced its position in shares of Opko Health Inc. (NYSE:OPK) by 6.1% during the second quarter, Holdings Channel reports. The firm owned 568,172 shares of the company’s stock after selling 36,880 shares during the period. Smith Graham & Co. Investment Advisors LP’s holdings in Opko Health were worth $5,307,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in the stock. Commonwealth Equity Services Inc increased its position in Opko Health by 4.6% in the first quarter. Commonwealth Equity Services Inc now owns 56,358 shares of the company’s stock valued at $586,000 after buying an additional 2,462 shares during the period. Aperio Group LLC increased its position in Opko Health by 67.1% in the first quarter. Aperio Group LLC now owns 63,042 shares of the company’s stock valued at $655,000 after buying an additional 25,312 shares during the period. Virginia Retirement System purchased a new position in Opko Health during the first quarter valued at about $510,000. Parametrica Management Ltd purchased a new position in Opko Health during the first quarter valued at about $336,000. Finally, Teachers Advisors Inc. increased its position in Opko Health by 3.6% in the first quarter. Teachers Advisors Inc. now owns 325,172 shares of the company’s stock valued at $3,379,000 after buying an additional 11,403 shares during the period.
Opko Health Inc. (NYSE:OPK) traded down 2.86% during mid-day trading on Wednesday, reaching $10.87. The company’s stock had a trading volume of 3,834,832 shares. The firm has a 50-day moving average of $9.93 and a 200 day moving average of $10.11. Opko Health Inc. has a 1-year low of $7.12 and a 1-year high of $11.85. The firm has a market capitalization of $5.98 billion and a price-to-earnings ratio of 45.48.
Opko Health (NYSE:OPK) last issued its earnings results on Monday, August 8th. The company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.05. The firm earned $357.10 million during the quarter, compared to analyst estimates of $324.11 million. During the same period in the previous year, the company earned ($0.09) earnings per share. The business’s revenue for the quarter was up 742.2% on a year-over-year basis. Equities analysts expect that Opko Health Inc. will post ($0.05) earnings per share for the current year.
Several research analysts have recently issued reports on the company. Standpoint Research assumed coverage on Opko Health in a research note on Friday, June 3rd. They set a “buy” rating and a $16.00 price target for the company. Oppenheimer Holdings Inc. reissued a “hold” rating on shares of Opko Health in a research note on Tuesday, May 31st. JPMorgan Chase & Co. set a $14.00 target price on shares of Opko Health and gave the company a “buy” rating in a research note on Tuesday, August 9th. Jefferies Group reissued a “hold” rating on shares of Opko Health in a research note on Wednesday, August 17th. Finally, Zacks Investment Research raised shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th. Five equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Opko Health has a consensus rating of “Buy” and a consensus price target of $13.20.
In other news, CEO Phillip Md Et Al Frost bought 48,400 shares of the company’s stock in a transaction on Thursday, August 25th. The shares were bought at an average cost of $9.06 per share, with a total value of $438,504.00. Following the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $27,804,696.06. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Opko Health Company Profile
OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.
Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opko Health Inc. (NYSE:OPK).
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.